Diabetes News: Metformin’s Brain Action - Daily Kos

What the report says

A Daily Kos Community post published July 27, 2026, highlighted new research on metformin, a long-used Type 2 diabetes medicine, reporting that scientists have identified a brain-related mechanism that may help explain how the drug lowers blood glucose. The post, written for the Kos Diabetes Group Community and not reviewed by Daily Kos staff before publication, cites Baylor College of Medicine material and social media discussion of a Science article.

According to the account, metformin appears to act not only through the liver and gut, as commonly understood, but also in the brain. The reported pathway involves suppressing a protein called Rap1 in the ventromedial hypothalamus, a brain region associated with metabolic regulation. The Baylor summary quoted in the post says that switching off Rap1 activates certain neurons linked to glucose control and that the effect was observed even at very small doses.

The post frames the finding as significant because metformin has been widely used for roughly six decades while its full mechanism has remained incompletely understood. It also notes familiar context about the drug, including that it is generally well tolerated but can cause gastrointestinal side effects such as diarrhea, nausea and abdominal pain; the author says they personally cannot take it because of severe diarrhea.

If confirmed and extended, the reported brain pathway could help guide research into diabetes treatments that more directly target central nervous system regulation of blood sugar. The Daily Kos item also briefly points readers to other metformin-related research areas, including studies involving long COVID, but the core development concerns metformin’s possible action in the brain.